Company DescriptionAileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeuticsfor the treatment of cancer and other diseases.

Proceeds PurposesIn particular, the financing will accelerate Aileron’s proprietary oncology clinical candidate, ALRN-6924, into clinical development in 2014 as a highly potent and specific re-activator of p53, a tumor suppressor protein that represents one of the most important oncology drug targets.